Docket Number: FDA-2019-D-1536 Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research
The purpose of this guidance is to describe the benefit-risk assessment framework that the 17 Agency uses in evaluating whether applications for opioid analgesic drugs meet the standard for 18 approval under section 505 of the Federal Food, Drug, and Cosmetic Act. This guidance 19 summarizes the information that should be included in a new drug application for an opioid 20 analgesic drug to facilitate the Agency’s benefit-risk assessment.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document’s docket number: FDA-2019-D-1536.
-
Content current as of:
05/13/2026
-
Regulated Product(s)
Topic(s)
